---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-26-000002"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:57:21.645780+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Supernus schedules Q4 2025 earnings release for Feb 24, 2026 after market close

## Summary
- Q4 and full year 2025 results to be reported after market close on February 24, 2026.
- Conference call and webcast at 4:30 p.m. ET on February 24, 2026, hosted by CEO Jack Khattar and CFO Tim Dec.
- No preliminary financial results or guidance provided in the announcement.

## SEC filing metadata
- accession: 0001356576-26-000002
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000002/0001356576-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000002/supn-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-26-000002
- JSON: https://secwatch.observer/filing/0001356576-26-000002.json
- Plain text: https://secwatch.observer/filing/0001356576-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.